Nonsteroidal therapy of sarcoidosis

Peter Korsten, Mehdi Mirsaeidi, Nadera J. Sweiss

Research output: Contribution to journalReview article

24 Scopus citations

Abstract

PURPOSE OF REVIEW: None of the medications used in clinical practice to treat sarcoidosis have been approved by the regulatory authorities. Understanding how to use disease-modifying antisarcoid drugs, however, is essential for physicians treating patients with sarcoidosis. This review summarizes the recent studies of medications used for sarcoidosis with a focus on nonsteroidal therapies. Studies from 2006 to 2013 were considered for review to update clinicians on the most relevant literature published over the last few years. RECENT FINDINGS: Several recently published pieces of evidence have helped expand our ability to more appropriately sequence second-line and third-line therapies for sarcoidosis. For instance, methotrexate and azathioprine may be useful and well tolerated medications as second-line treatment. Mycophenolate mofetil might have a role in neurosarcoidosis. TNF-α blockers and other biologics seem to be well tolerated medications for the most severely affected patients. SUMMARY: Corticosteroids remain the first-line therapy for sarcoidosis as many patients never require treatment or only necessitate a short treatment duration. Second-line and third-line therapies described in this article should be used in patients with progressive or refractory disease or when life-threatening complications are evident at the time of presentation.

Original languageEnglish (US)
Pages (from-to)516-523
Number of pages8
JournalCurrent Opinion in Pulmonary Medicine
Volume19
Issue number5
DOIs
StatePublished - Sep 2013

Keywords

  • Disease-modifying antisarcoid drugs
  • Sarcoidosis
  • TNF-α inhibitor
  • corticosteroids

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Nonsteroidal therapy of sarcoidosis'. Together they form a unique fingerprint.

  • Cite this